The industry trade association for health plans in Michigan wants greater clarity on how exactly state regulators view high-cost gene and cell therapies and their mandated coverage. In a response to a regulatory bulletin saying they must cover expensive gene and cell therapies, the Michigan Association of Health Plans notes…